- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT03999268
Insulin Start Therapy Application With Resources and Training (I-START)
7 luglio 2022 aggiornato da: Linda Siminerio, University of Pittsburgh
Evaluation of Insulin Start Therapy Application With Resources and Training (I-START) to Address Barriers to Insulin Therapy
The purpose of the I-START study is to evaluate an educational phone application (app) designed to support patients with type 2 diabetes (T2DM) by reinforcing the necessary skills needed for insulin administration as part of diabetes self-management.
Panoramica dello studio
Stato
Completato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Despite advances in technology and delivery systems, patients with T2DM continue to be reluctant to begin and adhere to insulin therapy for a variety of reasons.
Introducing insulin therapy is particularly problematic during a hospitalization or a brief routine outpatient visit given time and resource constraints.
Teaching people to administer an insulin injection requires time and ongoing support.
Therefore, this study aims to evaluate an educational phone application designed to support patients with T2DM by reinforcing skills and self-management behaviors needed for insulin administration.
Patients with T2DM who are starting insulin or need updated instruction on insulin will be invited to participate in this study to examine the effect of the phone app on psychological barriers to insulin as well as patient and provider satisfaction with and usability of the phone app in both outpatient and hospital settings.
Tipo di studio
Interventistico
Iscrizione (Effettivo)
41
Fase
- Non applicabile
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Luoghi di studio
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Stati Uniti, 15213
- University of Pittsburgh Medical Center
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
18 anni e precedenti (Adulto, Adulto più anziano)
Accetta volontari sani
No
Sessi ammissibili allo studio
Tutto
Descrizione
Inclusion Criteria:
- 18 years of age
- Able to read and follow study instructions in English (translations will not be provided)
- T2DM requiring the use of prandial and/or long-acting insulin
- Ability to self-administer insulin therapy
- Willing to download the study app on their smartphone
- Able and willing to provide a signed consent
- Able and willing to follow all study procedures
Exclusion Criteria:
- Pregnant (self-reported)
- Participants from the same household participating concurrently
- Use of a smartphone with iOS version 10.0 or lower
- Use of a smartphone with Android OS 5.0 "Lollipop" or lower
- Currently using a continuous subcutaneous insulin infusion device
- Participants with major depression
- Currently or planning to participate in a similar study that would affect the results of this study
- Currently or planning to participate in a clinical study that involves taking a drug, supplement, or use of an investigational drug
- Continued hospitalization or transfer to an assisted living facility
- Any condition the PI or designee deems to pose a risk to the participant in the study (includes anything that may prevent full participation in the study)
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Intervention
Participants assigned to the intervention group will receive insulin administration education according to standard procedures plus have access to the I-START app.
Over the course of the study period, participants will be able to use I-START as much or as little as they prefer.
|
Designed as a supplementary educational tool for patients on insulin therapy, I-START includes an injection plan to reinforce the knowledge and behaviors that users have been taught by their health care provider.
This is done through eight modules created for the benefit of new and experienced insulin users, and those using pens or vial/syringes.
The modules address a variety of topics pertinent to insulin therapy, including overcoming psychosocial barriers, injection techniques and best practices, managing hypo- and hyperglycemic events, monitoring blood glucose and troubleshooting and problem solving.
At the end of each module, users can self-evaluate their confidence in mastering the information presented.
This gives them the ability to move forward into the next module, repeat material already presented and/or save features of the modules that they would like to revisit at another time.
Standard best practices for training patients to administer insulin therapy include 1) a thorough patient assessment prior to therapy initiation to address barriers, including evaluation for diminished cognitive capacity or other problem that may impair safe insulin self-administration, and assessment of health literacy and numeracy skills; 2) observation of a patient's injection practice, with re-education provided as needed; 3) use of appropriate language is necessary when teaching injection technique; 4) dose preparation, which includes inspecting the insulin dose for accuracy (following manufacturer instructions); and 5) review of signs, symptoms and treatment of hypoglycemia must be included as a critical component of the training.
|
Comparatore attivo: Usual Care
Participants in the usual care group will receive insulin administration education according to standard procedures.
They will not have access to the I-START app.
|
Standard best practices for training patients to administer insulin therapy include 1) a thorough patient assessment prior to therapy initiation to address barriers, including evaluation for diminished cognitive capacity or other problem that may impair safe insulin self-administration, and assessment of health literacy and numeracy skills; 2) observation of a patient's injection practice, with re-education provided as needed; 3) use of appropriate language is necessary when teaching injection technique; 4) dose preparation, which includes inspecting the insulin dose for accuracy (following manufacturer instructions); and 5) review of signs, symptoms and treatment of hypoglycemia must be included as a critical component of the training.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Change from baseline in psychological insulin resistance at 2 weeks
Lasso di tempo: 2 weeks
|
Psychological insulin resistance will be assessed using the Barriers to Insulin Treatment Questionnaire (BIT), a short instrument that is easy to administer and may be used by both clinicians and researchers (Petrak et al, 2007).
The BIT Questionnaire includes 14 items, a total sum score, and the following five subscales: fear of injection and self-testing, expectations regarding positive insulin related outcomes, expected hardship from insulin treatment, stigmatization by insulin injection, and fear of hypoglycemia.
Each item is scored on a scale from 1 to 10, which are summed and averaged for total scores; the higher the score, the greater the level of concern.
|
2 weeks
|
Change from baseline in psychological insulin resistance at 3 months
Lasso di tempo: 3 months
|
Psychological insulin resistance will be assessed using the Barriers to Insulin Treatment Questionnaire (BIT), a short instrument that is easy to administer and may be used by both clinicians and researchers (Petrak et al, 2007).
The BIT Questionnaire includes 14 items, a total sum score, and the following five subscales: fear of injection and self-testing, expectations regarding positive insulin related outcomes, expected hardship from insulin treatment, stigmatization by insulin injection, and fear of hypoglycemia.
Each item is scored on a scale from 1 to 10, which are summed and averaged for total scores; the higher the score, the greater the level of concern.
|
3 months
|
Change from baseline in psychological insulin resistance at 6 months
Lasso di tempo: 6 months
|
Psychological insulin resistance will be assessed using the Barriers to Insulin Treatment Questionnaire (BIT), a short instrument that is easy to administer and may be used by both clinicians and researchers (Petrak et al, 2007).
The BIT Questionnaire includes 14 items, a total sum score, and the following five subscales: fear of injection and self-testing, expectations regarding positive insulin related outcomes, expected hardship from insulin treatment, stigmatization by insulin injection, and fear of hypoglycemia.
Each item is scored on a scale from 1 to 10, which are summed and averaged for total scores; the higher the score, the greater the level of concern.
|
6 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Change from baseline in glycemic control at 3 months
Lasso di tempo: 3 months
|
Hemoglobin A1c (HbA1c) will serve as a clinical indicator of glycemic control.
HbA1c will serve as the clinical study outcome and measure of glycemic control.
HbA1c values will be obtained from the electronic medical record (EMR) system.
|
3 months
|
Change from baseline in glycemic control at 6 months
Lasso di tempo: 6 months
|
Hemoglobin A1c (HbA1c) will serve as a clinical indicator of glycemic control.
HbA1c will serve as the clinical study outcome and measure of glycemic control.
HbA1c values will be obtained from the electronic medical record (EMR) system.
|
6 months
|
Change from baseline in medication adherence at 3 months
Lasso di tempo: 3 months
|
Medication adherence will be assessed with the 8-item Morisky Medication Adherence Scale (MMAS-8).
The scales includes 8 items.
Scores can range from 0 to 8; the higher the score, the more adherent the respondent is considered.
|
3 months
|
Change from baseline in medication adherence at 6 months
Lasso di tempo: 6 months
|
Medication adherence will be assessed with the 8-item Morisky Medication Adherence Scale (MMAS-8).
Scores can range from 0 to 8; the higher the score, the more adherent the respondent is considered.
|
6 months
|
Change from baseline in diabetes empowerment at 3 months
Lasso di tempo: 3 months
|
Empowerment will be measured using the 8-item Diabetes Empowerment Scale-Short Form (DES-SF), which measures an individual's perceived ability to manage psychosocial aspects of diabetes, assess dissatisfaction and readiness to change self-management plans and set and achieve diabetes goals (Anderson et al, 2000; Anderson et al, 2003).
Possible scores are 1 to 5 for each item, summed for a possible total score of 8 to 40.
Higher scores indicate greater empowerment.
|
3 months
|
Change from baseline in diabetes empowerment at 6 months
Lasso di tempo: 6 months
|
Empowerment will be measured using the 8-item Diabetes Empowerment Scale-Short Form (DES-SF), which measures an individual's perceived ability to manage psychosocial aspects of diabetes, assess dissatisfaction and readiness to change self-management plans and set and achieve diabetes goals (Anderson et al, 2000; Anderson et al, 2003).
Possible scores are 1 to 5 for each item, summed for a possible total score of 8 to 40.
Higher scores indicate greater empowerment.
|
6 months
|
Change from baseline in diabetes distress at 3 months
Lasso di tempo: 3 months
|
Diabetes distress will be evaluated with the 17-item Diabetes Distress Scale (DDS17), which assesses four dimensions of distress - emotional, regimen, interpersonal and physician (Polonsky et al, 2005), and has shown a consistent pattern of relationships with HbA1c, diabetes self-efficacy, diet and physical activity in multiple samples of patients with T2DM (Fisher et al, 2012).
Individual items are scored from 1 to 6; total scores are the average of all individual item scores; higher scores indicate greater distress.
|
3 months
|
Change from baseline in diabetes distress at 6 months
Lasso di tempo: 6 months
|
Diabetes distress will be evaluated with the 17-item Diabetes Distress Scale (DDS17), which assesses four dimensions of distress - emotional, regimen, interpersonal and physician (Polonsky et al, 2005), and has shown a consistent pattern of relationships with HbA1c, diabetes self-efficacy, diet and physical activity in multiple samples of patients with T2DM (Fisher et al, 2012).
Individual items are scored from 1 to 6; total scores are the average of all individual item scores; higher scores indicate greater distress.
|
6 months
|
Patient Satisfaction
Lasso di tempo: 6 months
|
Patient satisfaction will be assessed using the validated Diabetes Medication System Rating Questionnaire-Short Form (DMSRQ-SF) (Peyrot et al, 2014).
Items are scored 0 to 100; higher scores equal greater levels of item/construct being measured.
|
6 months
|
Provider Satisfaction
Lasso di tempo: 6 months
|
Clinician experiences and perspectives on satisfaction of the app will be assessed through a study specific satisfaction survey
|
6 months
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Patient Usability
Lasso di tempo: 6 months
|
Patient usability will be tracked through the app's data analytics software platform.
Study staff will pull data from the data analytics software platform.
|
6 months
|
Provider usability
Lasso di tempo: 6 months
|
Clinician experiences and perspectives on the usability of the Briight app will be assessed a study specific usability survey.
|
6 months
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Investigatori
- Investigatore principale: Linda Siminerio, RN, PhD, CDE, professor
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio (Effettivo)
25 novembre 2019
Completamento primario (Effettivo)
25 maggio 2022
Completamento dello studio (Effettivo)
25 maggio 2022
Date di iscrizione allo studio
Primo inviato
21 giugno 2019
Primo inviato che soddisfa i criteri di controllo qualità
25 giugno 2019
Primo Inserito (Effettivo)
26 giugno 2019
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
8 luglio 2022
Ultimo aggiornamento inviato che soddisfa i criteri QC
7 luglio 2022
Ultimo verificato
1 luglio 2022
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- STUDY19040017
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
SÌ
Descrizione del piano IPD
De-identified data set used for final analysis will be made available to other researchers who have obtained appropriate regulatory approval
Periodo di condivisione IPD
Data Set - After publication.
ICF - After completing data collection.
Criteri di accesso alla condivisione IPD
Data set - other researchers will have to request access.
ICF will be added to clinicaltrials.gov
protocol
Tipo di informazioni di supporto alla condivisione IPD
- ICF
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
No
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
No
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su I-START
-
University of MemphisUSANA Health SciencesReclutamentoPerdita di pesoStati Uniti
-
Nanyang Technological UniversityNational Kidney Foundation, SingaporeReclutamentoMalattia renale allo stadio terminale | Malattia renale allo stadio terminale | Insufficienza renale allo stadio terminale in dialisi | Malattia renale allo stadio terminale in dialisiSingapore
-
Universidad Santo TomasUniversidad Pública de NavarraCompletatoAttività fisica | Sindrome da deficit di attenzione e iperattività | Comportamento del bambino | ComportamentoChile
-
University of New MexicoNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Terminato
-
Arizona State UniversityReclutamento
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); BC Children's Hospital Research... e altri collaboratoriReclutamentoPratiche genitoriali | Pratiche di co-genitorialità | Comportamenti alimentari e dietetici del bambino | Attività fisica del bambino/Gioco attivo/Gioco all'aperto | Tempo sullo schermo del bambinoCanada
-
Arizona State UniversityReclutamentoIctus | Afasia | Aprassia della parolaStati Uniti
-
University College CorkCompletatoReazione avversa al farmacoIrlanda
-
Texas Scottish Rite Hospital for ChildrenReclutamentoParalisi cerebrale unilaterale | Prontezza scolasticaStati Uniti
-
VA Office of Research and DevelopmentReclutamentoDisturbo da Uso di Sostanze | Malattia mentale | Recentemente incarceratoStati Uniti